Andy Jerome

@DanielJDrucker @AppleHelix Its not clear if this is a true mechanism or if this is a PK effect. Probably the former IMO

As the weight loss-independent actions of GLP-1 medicines unfold a greater reduction in PsA disease activity (ACR50) was seen as early as Week 4 in the Ixekizumab and Tirzepatide treatment arm before clinically meaningful weight loss was observed investor.lilly.com/news-releases/…

In this piece, my mentor Stu Orkin and I (1) marvel at prime editing—discovery to disease correction for 2 patients after just 6 yr—wow Liu, Anzalone, Gori, Malech et al! & (2) consider the challenges to deliver genetic medicine’s promise for 2^n patients nejm.org/doi/full/10.10…

The "poster" section for AAD - a row of computers. I find a lot of good data on preclinical drug programs walking poster sections at conferences... I guess this is the future. There are more poster presetatios than other conferences #AAD

@ohadhammer There are a few more MOA's in the pipeline than this but this covers most of them. The most common Mult specifics are an alarmin (TSLP or IL33) with IL13/IL4 - this combination is the most promising IMO. Despite the historical failures of alarmin monotherapies

Atopic dermatitis landscape from Wedbush. Looks like there are two parallel vectors: lower injection frequency ( $APGE ) and combining new mechanisms with IL13/IL4R. So far $JNJ's IL13+IL31 failed (the only one to be directly compared to dupi) while $PFE's IL13+TSLP and $UCB's IL13+IL17A/F demonstrated a 50% pbo-adjusted EASI75 but without a dupi comparator arm (historical EASI75 of ~35%). IL13+OX40 will be an interesting one but class has a safety overhang.

𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 | 𝐍𝐞𝐰 𝐃𝐚𝐭𝐚: Apogee Therapeutics is announcing topline 52 week APEX Part A results in AD for its extended-dosing IL-13 inhibitor, zumilokibart. $APGE

@semodough A little higher than either dupi or lebri but still within the expected range. I view it as a success but keep in mind lebri is currently testing Q12W maintenance dosing which if positive takes a lot of the wind out the apogee's sails

$APGE Across the 52-week treatment period, the most common TEAEs were noninfective conjunctivitis, upper respiratory tract infection, and nasopharyngitis. But not seeing the % ???

#AAD2026 poster titles and abstracts are finally available eposters.aad.org

And this is why I don’t run

@ideapharma Of course! It's literally on the pitch deck for biotech out there right now... I wish I were joking 🙃

Wow - I just saw that Sanofi’s new tagline is (yes, really…) “AI driven R&D company” If I took ‘Sanofi’ off this slide, would you have any idea which company this is? 😅

@AutismCapital Washingtonian born and raised, I moved away for 10yrs, living in multiple states across the US, and moved back. The wealthy need to ask themselves for a state with "No income tax" written into it's constitution what changed why was this so popular? FYI I 100% support this.

🚨BREAKING: Washington State passes their first ever income tax. Incomes over $1M/year will be taxed at 9.9%. Married couples share A SINGLE $1M exemption, so if combined incomes are more than $1M, you're getting taxed. This will obviously eventually extend beyond millionaires. What comes for others, will eventually come for you! RIP Washington state!

UCB announced topline results of the BE-BOLD head-to-head study where bimekizumab (IL-17i) was superior to risankizumab (IL-23i) study; 553 active PsA in achieving an ACR50 response at 16 weeks. Enrolled PsA pts were either bilogic naïve or who had previous exposure to 1 TNFi ucb-usa.com/stories-media/…

@A_May_MD @semodough Intresting take... though I dont believe Nektar included biologic failures in the Ph2 study (inclusion criteria for Ph 3 are still undecided). Everyone in the pipeline will be behind dupi... its the question of who will actually work in these patients

I swear I've never seen a market understand a disease/disease landscape worse than atopic derm. The $NKTR and $APGE price actions are absolutely WRONG today, and I'll tell you why. Apparently (?) the market is selling $NKTR today because of $PFE data with their phase 2 IL4/13+TSLP data this morning. If you asked me before the market opened if I thought this would affect $NKTR at all I would've said "no". In fact, in private conversations before open I did just that. The $PFE drug is yet another IL4/13 axis drug, adding in TSLP, which has a checkered past and may or may not actually add to IL4/13 blockade (there is both some reason to believe that the target is not active in AtD at al and/or that it is not additive to IL4/13 since these are all heavily TH2-skewed targets). The $PFE drug vies for first line positioning, where IL4/13 is used... ...for the millionth time...THE ENTIRE POINT OF $NKTR'S DRUG IS TO BE USED ***AFTER*** IL4/13 DRUGS. There is no world in which a patient should fail an IL4/13+TSLP drug and then go onto a plain old IL4/13 drug....This is where a completely differentiated MoA like NKTR's is needed...this is the *ENTIRE* point of the drug... So who could the $PFE news actually significantly affect? $APGE!!! $APGE is trying to develop long acting IL4/13 drugs to take their share of this first line IL4/13 market...the $PFE news gives them a DIRECT competitor in that market, with $PFE's drug adding an extra MoA that $APGE lacks. $APGE went with OX40 as their IL4/13 combo partner target, because they observed that TSLP had failed in prior trials and that the TSLP pathway simply overlaps with IL4/13 (meaning it might be a redundant target). $APGE went with OX40, which as we all now know is potentially dead in AtD due to cancer risks. So, $APGE should be down today, right? Right?! They now have a direct competitor in $PFE that is vying for space in their same line of therapy/target. New competitive risk, right?! Well, $APGE is *GREEN* today, while $NKTR is -10%. This. Market. Reaction. Is. Wrong. Period. These price actions should be reversed by any sane logic. If you want to argue $APGE should be flat/green because the AtD market is so massive that it can handle more drugs, then fine. But there is absolutely ZERO reason for $NKTR to be -10% while $APGE is green on this "news". $PFE is a DIRECT competitor for $APGE versus an oblique competitor for $NKTR at worst. I cannot comprehend how it is possible that people STILL do not understand the "differentiated MoA" use case of $NKTR's rezpeg. It is truly hard for me to fathom how a market can be this STUPID and inefficient. As far as market inefficiencies go, the AtD space is the gift that keeps on giving. Absolutely insane. Yet again, moving more stuff to buy $NKTR -10%. I'd love short more $APGE >$73 too...but alas, capital constraints push more to the better r/r of the two. There's clearly no competition there AFAIC.

I hope to be him someday

Yeah - time to move beyond the regressive tax system of Washington state which penalized family and rewards permanent DINKs

@arielyemini1 @Xtian375 The really sad part is that the people in Iran would make fantastic allies.They are a wonderful people. They've lived under nightmarish conditions for far too long. I just wish we weren't giving them the Iraq/Afghanistan/Libya treatment. Their lives are already hard.

No one in DC ever asks, "How are you going to pay for this latest war?" But healthcare, childcare, every other progressive policy proposal is met with the same kneejerk, "How are you going to pay for this?" It's infuriating.

How is this not getting more attention... it kills one of two late stage programs in development for atopic dermatitis and casts a large shadow over the other $SNY This is huge! kkna.kyowakirin.com/media-center/k…

The greatest insurance scam of the 21th century continues...

$GENB Generate scores the largest #biotech IPO since 2024 with $400M Nasdaq listing. $XBI fiercebiotech.com/biotech/genera…

As a former U.S. Surgeon General who held an active medical license and practiced medicine while in the role (at Walter Reed and aboard the USS Comfort) it is incomprehensible that the Senate is even considering a nominee for this role who lacks any active license and has never practiced unsupervised. 🤯